Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H2 2016’, provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Merck & Co Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Tissue Therapies Ltd

TWi Pharmaceuticals Inc

Vascular Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview 7

Therapeutics Development 8

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Stage of Development 8

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Therapy Area 9

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Indication 10

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Companies 15

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Universities/Institutes 17

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development 26

Merck & Co Inc 26

SciFluor Life Sciences LLC 27

SOM Biotech SL 28

Tissue Therapies Ltd 29

TWi Pharmaceuticals Inc 30

Vascular Pharmaceuticals Inc 31

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles 32

A-11 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AC-301 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

C-16Y - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cilengitide - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MK-0429 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

OCU-200 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Proagio - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Recombinant Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

RSF-201 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

RUC-4 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

SF-0166 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

SOM-0777 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

tetraiodothyroacetic acid - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

VF-001 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VPI-2690B - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Projects 50

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products 55

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Featured News & Press Releases 56

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001) 56

Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution 56

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US 57

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board 57

Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases 59

May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 60

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 61

Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 61

Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 62

Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 63

Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma 64

Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide’s Pivotal Phase III Trial CENTRIC 65

Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients 66

May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 67

Mar 16, 2009: Merck Serono Expands Cilengitide Development Program 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Merck & Co Inc, H2 2016 26

Pipeline by SciFluor Life Sciences LLC, H2 2016 27

Pipeline by SOM Biotech SL, H2 2016 28

Pipeline by Tissue Therapies Ltd, H2 2016 29

Pipeline by TWi Pharmaceuticals Inc, H2 2016 30

Pipeline by Vascular Pharmaceuticals Inc, H2 2016 31

Dormant Projects, H2 2016 50

Dormant Projects (Contd..1), H2 2016 51

Dormant Projects (Contd..2), H2 2016 52

Dormant Projects (Contd..3), H2 2016 53

Dormant Projects (Contd..4), H2 2016 54

Discontinued Products, H2 2016 55

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports